21 Years Later: Has Executive Order 12898 (entitled Federal Actions to Address Environmental Justice in Minority Populations and Low-income Populations) worked?
We used principles of legal epidemiology to conduct policy surveillance using established protocols to examine the impact of EO 12898 on public health law (including environmental laws and regulation). We began by collecting documents referencing EO 12898 using LEXIS and Regulations.gov. In the initial examination we took a random sampling across all agencies (from the promulgation of 12898 until February 1, 2014) and reviewed every tenth document against preset codes using LawAtlas WorkBench. Coders crosschecked each other’s work to determine consistency. Next, we evaluated the actions of US EPA, US DOI and USCG from February 1, 2014 through February 1, 2015 to consider how EO12898 impacted specifically environmental regulation. Our review concluded that there was no evidence that EO 128988 had altered proposed environmental or health regulations or significantly improved environmental injustices. Across the board, federal agencies treated EO 12898 as boilerplate needed complete OMB review.
Learning Areas:Environmental health sciences
Public health or related laws, regulations, standards, or guidelines
Public health or related public policy
Analyze the effectiveness of Executive Order 12898, Federal Actions to Address Environmental Justice in Minority Populations and Low-income Populations Discuss how Executive Order 12898 (Federal Actions to Address Environmental Justice in Minority Populations and Low-income Populations) can be modified or used more effectively to improve environmental justice across the country
Keyword(s): Environmental Justice, Environmental Health
Qualified on the content I am responsible for because: I am an author of 17 books on environmental policy. I am also an associate professor and program director of environmental health sciences as a major urban school of public health.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.